Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
<!-- Name:DistributionId Value:8795195 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
BioPath
Bio-Path Holdings Announces First Patient Dosed in Phase 1/1b Clinical Trial of BP1001-A in Solid…
HOUSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid…
Bio-Path Holdings Presents BP1003 Data at 2022 American Association for Cancer Research Annual…
HOUSTON, April 12, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid…
Bio-Path Holdings to Announce Third Quarter 2021 Financial Results on November 12, 2021
HOUSTON, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid…